|
| Press Releases |
|
 |
|
| Tuesday, December 15, 2020 |
|
|
德琪醫藥中長線價值俱佳 未來兩年陸續收成 |
| 中國生物科技股行業前景佳，市場對創新醫藥的需求隨著醫療服務質量的持續提升而擴大，尤其在抗腫瘤及免疫系統相關治療領域，未來市場新增需求更有望迎來黃金機遇。 more info >> |
|
| Friday, November 20, 2020 |
|
|
覆蓋亞太地區的一體化創新腫瘤藥公司德琪醫藥有限公司於香港聯合交易所主板掛牌 |
| 德琪醫藥有限公司（「德琪醫藥」或「公司」，連同其附屬公司，統稱「集團」；股份代號：6996.HK），一家面向亞太、佈局全球，集新藥開發、臨床研究於一體的臨床階段生物醫藥公司，今天於香港聯合交易所有限公司（「港交所」）主板正式掛牌並開始交易。 more info >> |
|
|
Antengene Corporation Successfully Listed on Main Board of SEHK |
| Antengene Corporation Limited ("Antengene" or the "Company", together with its subsidiaries, the "Group", stock code: 6996.HK), a clinical-stage biopharmaceutical company with integrated drug discovery, clinical development, anchored in Asia-Pacific (APAC) with a global layout, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today. more info >> |
|
| Monday, July 20, 2020 |
|
|
德琪醫藥C輪融資9700萬美元，主要用於新藥研發和商業化 |
| 專注於研發和商業化腫瘤領域全新機制及同類最優創新藥的領導企業——德琪醫藥，今日宣佈完成9700萬美元C輪融資。 more info >> |
|
|
德琪医药C轮融资9700万美元，主要用于新药研发和商业化 |
| 专注于研发和商业化肿瘤领域全新机制及同类最优创新药的领导企业——德琪医药，今日宣布完成9700万美元C轮融资。 more info >> |
|
|
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization |
| Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, today announced that it has successfully closed US$97 million in Series C financing. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 6, 2026 20:00 JST
|
|
|
Xunce (3317.HK) Released Profit Alert: Revenue Doubles, Surpasses Expectations by a Wide Margin, China's Palantir Rises!
Mar 6, 2026 18:23 HKT/SGT
|
|
|
迅策(3317.HK)發佈盈利預告：營收翻翻 大超預期 中國版Palantir崛起！
Mar 6, 2026 18:17 HKT/SGT
|
|
|
迅策(3317.HK)发布盈利预告：营收翻翻 大超预期 中国版Palantir崛起！
Mar 6, 2026 18:00 HKT/SGT
|
|
|
香港實現綠色甲醇首船加注 推動國際航運中心綠色轉型
Mar 6, 2026 15:40 HKT/SGT
|
|
|
香港实现绿色甲醇首船加注 推动国际航运中心绿色转型
Mar 6, 2026 15:31 HKT/SGT
|
|
|
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 6, 2026 15:05 HKT/SGT
|
|
|
Hong Kong Tech Innovators Drive Success at Mobile World Congress and 4YFN Barcelona 2026
Mar 6, 2026 13:08 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 6, 2026 12:12 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Mar 6, 2026 10:00 HKT/SGT
|
|
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
美國馬球協會擴大大學合作計畫 2026賽季隊伍數創紀錄達70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
美国马球协会扩大大学合作计划，2026赛季参赛队伍创纪录达70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 17:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
